<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145961</url>
  </required_header>
  <id_info>
    <org_study_id>ICR-CTSU/2016/10058</org_study_id>
    <secondary_id>2017-000508-92</secondary_id>
    <nct_id>NCT03145961</nct_id>
  </id_info>
  <brief_title>A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients</brief_title>
  <acronym>c-TRAK-TN</acronym>
  <official_title>c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA)
      screening component and a therapeutic component. c-TRAK TN aims to assess whether ctDNA
      screening can be used to detect residual disease following patients standard primary
      treatment for triple negative breast cancer, and will assess the safety and activity of the
      investigational medicinal product pembrolizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo blinded serial ctDNA screening every 3 months from the point of
      registration and completion of primary treatment for their triple negative breast cancer. If
      a ctDNA positive result occurs on or before their 12 month ctDNA screening assessment they
      will be randomised by the Institute of Cancer Research Clinical Trials and Statistics Unit
      (ICR-CTSU) in a 2:1 ratio to the pembrolizumab treatment arm or observation arm. The patient
      and their treating team will only be informed of the randomisation if they are allocated
      treatment.

      Patients without a positive ctDNA result within 12 months of starting ctDNA screening, will
      not be randomised but will continue to have blinded ctDNA screening every 3 months up to 2
      years from starting ctDNA screening.

      All patients will be followed up every 6 months until recurrence, specific withdrawal of
      consent for follow up, or until sponsor advises no further follow up is required.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patients will undergo blinded serial ctDNA screening every 3 months from the point of registration and completion of primary treatment for their triple negative breast cancer. If a ctDNA positive result occurs on or before their 12 month ctDNA screening assessment the patient will be randomised by the ICR-CTSU in a 2:1 ratio to the pembrolizumab treatment arm or observation arm. The patient and their treating team will only be informed of the randomisation if they are allocated to the treatment arm.
For patients allocated to the observation group, the treating team and patient will not be informed that randomisation has taken place in order to remain blinded to the positive ctDNA result. Such patients will continue to have blood samples collected for ctDNA analysis every 3 months up to 2 years from starting ctDNA screening.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Positive ctDNA detection by 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of patients with ctDNA positivity by 12 months as assessed by the blood sample taken at that timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive ctDNA detection by 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>The proportion of patients with ctDNA positivity by 24 months as assessed by the blood sample taken at that timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of detectable ctDNA or disease recurrence 6 months (24 weeks) after commencing pembrolizumab</measure>
    <time_frame>6 months (24 weeks) after commencing pembrolizumab</time_frame>
    <description>The proportion of patients without either detectable ctDNA or disease recurrence 6 months (24 weeks) after starting pembrolizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ctDNA detection</measure>
    <time_frame>Baseline to first ctDNA positivity (up to a maximum of 12 months after starting ctDNA surveillance)</time_frame>
    <description>The time from entry into ctDNA surveillance to first positive ctDNA detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of overt metastatic disease at time of first ctDNA detection in patients allocated to pembrolizumab</measure>
    <time_frame>Baseline to first ctDNA positivity (up to a maximum of 12 months after starting ctDNA surveillance)</time_frame>
    <description>Proportion of patients with metastatic disease at the same time point as first positive ctDNA detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lead time between ctDNA detection and disease recurrence in the pembrolizumab treatment and observation groups</measure>
    <time_frame>From date of randomisation to recurrence detection, expected to occur up to 5 years</time_frame>
    <description>The time between randomisation to the therapeutic aspect of the trial (either to pembrolizumab treatment or observation group) and first confirmed detection of recurrent disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of detectable ctDNA or disease recurrence after 6 months in the observation group</measure>
    <time_frame>6 months after randomisation</time_frame>
    <description>Proportion of patients without detectable ctDNA or disease recurrence 6 months after randomisation to observation group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of pembrolizumab assessed using NCI CTCAE v4.0, and the proportion of patients reporting dose reductions or delays.</measure>
    <time_frame>Throughout pembrolizumab treatment, up to 12 months of treatment</time_frame>
    <description>Adverse events assessed throughout treatment period, using the NCI CTCAE v4.0. Proportion of patients reporting a dose reduction or delay will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Commencement of treatment in patients randomised to receive pembrolizumab</measure>
    <time_frame>At point of commencement or non-commencement of treatment, up to 8 weeks following randomisation</time_frame>
    <description>Proportion of patients randomised to receive pembrolizumab who start the therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Descriptive differences in time between ctDNA detection and disease recurrence, and disease free survival, between patients in the pembrolizumab and the observation groups</measure>
    <time_frame>Time between first ctDNA detection and documented recurrence or disease free survival event, whichever comes first, expected to occur up to 5 years</time_frame>
    <description>Time from first positive ctDNA detection to disease recurrence or disease-free survival event.</description>
  </other_outcome>
  <other_outcome>
    <measure>To explore predictors of sustained ctDNA clearance on pembrolizumab.</measure>
    <time_frame>6-12 months after commencing pembrolizumab</time_frame>
    <description>The relationship between sustained clearance of ctDNA on pembrolizumab and biological markers will be summarised and investigated using logistic regression.</description>
  </other_outcome>
  <other_outcome>
    <measure>To explore potential predictors of relapse and ctDNA detection, and alternative definitions of ctDNA clearance</measure>
    <time_frame>Baseline to point of disease recurrence, expected to occur up to 5 years</time_frame>
    <description>Relationship between lead time and clinical/biological factors will be assessed using standard statistical techniques for time to event data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Association between ctDNA clearance and time to recurrence in pembrolizumab group</measure>
    <time_frame>Time of ctDNA clearance to time of recurrence, expected to occur up to 5 years</time_frame>
    <description>Relationship between ctDNA clearance and time to recurrence in the pembrolizumab group will be assessed using standard statistical techniques for time to event data.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200mg intravenous infusion</description>
    <arm_group_label>Pembrolizumab Treatment</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form for Registration

          2. Male or female patients ages 16 years or older

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          4. Histologically proven primary triple negative breast cancer as defined as oestrogen
             receptor (ER) negative, progesterone receptor (PgR) negative (if available, otherwise
             PgR unknown), (as defined by Allred score 0/8 or 2/8 or stain in &lt;1% of cancer cells)
             and human epidermal growth factor receptor 2 (HER2) negative (immunohistochemistry
             0/1+ or negative by in situ hybridization) as determined by local laboratory.

          5. Availability of tissue from two archival tumour tissue samples (either from diagnostic
             biopsy, and/or primary surgery. If only one tumour sample is available, the site
             should inform the ICR-CTSU who will discuss eligibility with the Chief Investigator or
             the designated Trial Management Group (TMG) member. Patients who have tumours
             previously sequenced outside the c-TRAK TN trial must provide one archival tumour
             tissue sample and the report that confirms the mutations detected.

          6. Patients with moderate or high risk early stage triple negative breast cancer
             according to the following risk of relapse criteria:

             Neoadjuvant chemotherapy (no adjuvant chemotherapy planned):

             High risk criteria - Residual microscopic or macroscopic invasive cancer in the
             axillary nodes after chemotherapy Moderate risk criteria - Residual invasive cancer in
             the breast, and axillary lymph node negative after chemotherapy

             Adjuvant chemotherapy:

             High risk criteria - Tumour size &gt;50mm and node positive OR â‰¥4 nodes positive
             regardless of primary tumour size.

             Moderate risk criteria - Tumour size &gt;20mm AND/OR involved axillary macroscopic lymph
             node.

             Both neoadjuvant and adjuvant chemotherapy:

             Patients who have received both neoadjuvant chemotherapy and further adjuvant
             chemotherapy must fulfil only the adjuvant chemotherapy risk criteria to be eligible.
             They can fulfil the criteria on either clinical staging prior to neoadjuvant
             chemotherapy or pathological staging at surgery.

          7. Patients must be registered according to the following criteria for timing of
             registration:

             Neoadjuvant chemotherapy (no adjuvant chemotherapy planned):

             Patients must be registered within 6 weeks of surgery. Patients may be registered
             before or during radiotherapy and should be registered as early as possible.

             Adjuvant chemotherapy (no neoadjuvant chemotherapy received):

             Patients must be registered before, or on the day of, the 3rd cycle of adjuvant
             chemotherapy and should be registered as early as possible.

             Both neoadjuvant and adjuvant chemotherapy Patients must be registered within 6 weeks
             of surgery. Patients may be registered before or during radiotherapy. Patients must
             register before starting capecitabine.

          8. Consent to provide research blood samples.

          9. Patients with bilateral tumours can be included if both are triple negative and if two
             archival tissues samples can be provided per tumour.

         10. Patients must have had surgery achieving clear margins (as per local guidelines).

         11. Female and male patients of reproductive potential must be willing to use an adequate
             method of contraception, for the first year of the trial and if randomised to
             pembrolizumab, for the duration of treatment through to 120 days after the last dose
             of pembrolizumab. Note: Abstinence is acceptable if this is the usual lifestyle and
             preferred contraception for the patient.

         12. Patients must be willing to have frequent blood tests (every 3 months for 2 years in
             ctDNA screening and 3 weekly if subsequently allocated pembrolizumab) and receive a 12
             month course of pembrolizumab if randomised to pembrolizumab treatment on ctDNA
             detection.

         13. No evidence of distant metastatic disease on staging scans conducted at any time since
             initial diagnosis

        NB: Additional eligibility criteria apply to confirm eligibility to commence pembrolizumab
        treatment following randomisation.

        Exclusion Criteria:

          1. Any concurrent or planned treatment for the current diagnosis of breast cancer other
             than surgery, locoregional adjuvant radiotherapy, standard neoadjuvant or adjuvant
             chemotherapy, or a bisphosphonate/denosumab.

          2. Prior treatment with a programmed death ligand 1(PDL1), programmed cell death protein
             1 (PD1), or other immunomodulatory therapy.

          3. Prior diagnosis of cancer including prior diagnosis of breast cancer in the previous 5
             years, other than for basal cell carcinoma of the skin or cervical carcinoma in situ

          4. Patients previously entered into a therapeutic trial during or after neoadjuvant
             chemotherapy where experimental therapy is continued post-surgery.

          5. Treatment with an unlicensed or investigational product within 4 weeks of trial entry.

          6. Active autoimmune disease requiring systemic therapy in the last two years (i.e. with
             use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (e.g. thyroxine, insulin or physiologic corticosteroid replacement
             therapy for adrenal or pituitary insufficiency) is not considered a form of such
             systemic treatment.

          7. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
             of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab.

          8. Known history of active Tuberculosis Bacillus (TB).

          9. Known history of Human Immunodeficiency Virus (HIV).

         10. Known active Hepatitis B or Hepatitis C.

         11. Known history of, or any evidence of active, non-infectious pneumonitis.

         12. Active infection requiring systemic therapy.

         13. Previous solid organ or allogenic stem cell transplantation

         14. Females who are pregnant or breastfeeding.

         15. Presence of any systemic illness incompatible with participation in the clinical trial
             or inability to provide written informed consent.

        NB. Additional exclusion criteria apply to confirm eligibility to commence pembrolizumab
        treatment following randomisation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Turner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden Hospital, Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>London</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital, Sutton</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hopitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer early stage</keyword>
  <keyword>circulating tumour DNA</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>randomised clinical trial</keyword>
  <keyword>phase II</keyword>
  <keyword>mutation screening</keyword>
  <keyword>intermediate endpoint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Formal requests for data sharing will be considered in line with ICR-CTSU procedure with due regard given to funder and sponsor guidelines. Requests are via a standard pro forma describing the nature of the proposed research and extent of data requirements. Data recipients are required to sign a data release form which describes the conditions for release and requirements for data transfer, storage, archiving, publication and Intellectual Property.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

